KR20070122056A - 콜로이드 금의 아쥬반트로의 사용 - Google Patents
콜로이드 금의 아쥬반트로의 사용 Download PDFInfo
- Publication number
- KR20070122056A KR20070122056A KR1020060057040A KR20060057040A KR20070122056A KR 20070122056 A KR20070122056 A KR 20070122056A KR 1020060057040 A KR1020060057040 A KR 1020060057040A KR 20060057040 A KR20060057040 A KR 20060057040A KR 20070122056 A KR20070122056 A KR 20070122056A
- Authority
- KR
- South Korea
- Prior art keywords
- colloidal gold
- antigen
- adjuvant
- vaccine
- immune response
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/242—Gold; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
Abstract
Description
Claims (14)
- 콜로이드 금을 포함하는 아쥬반트 조성물.
- 제1항에 있어서, 콜로이드 금이 단백질로 코팅된 콜로이드 금 결합체 형태인 아쥬반트 조성물.
- 제2항에 있어서, 콜로이드 금이 BSA 또는 항원 단백질로 코팅된 콜로이드 금 결합체 형태인 아쥬반트 조성물.
- 제1항에 있어서, 상기 조성물이 세포성 면역을 증가시키는 것인 아쥬반트 조성물.
- 제1항에 있어서, 치료 백신용의 아쥬반트 조성물.
- 제1항에 있어서, 콜로이드 금의 직경이 5 내지 100nm인 아쥬반트 조성물.
- 제6항에 있어서, 콜로이드 금의 직경이 10 내지 40nm인 아쥬반트 조성물.
- 제1항의 조성물과 항원을 포함하는 백신 조성물.
- 제8항에 있어서, 콜로이드 금 이외의 아쥬반트 성분을 추가로 포함하는 백신 조성물.
- 제9항에 있어서, 알룸을 추가로 포함하는 백신 조성물.
- 제8항에 있어서, 상기 항원이 바이러스에서 기원한 항원인 백신 조성물.
- 제8항에 있어서, 상기 조성물이 세포성 면역을 증가시키는 것인 백신 조성물.
- 제8항에 있어서, 치료용 백신 조성물.
- 콜로이드 금을 아쥬반트로 사용하여 항원에 의해 유도되는 세포성 면역을 증가시키는 방법.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060057040A KR100836893B1 (ko) | 2006-06-23 | 2006-06-23 | 콜로이드 금의 아쥬반트로의 사용 |
PCT/KR2007/003002 WO2007148924A1 (en) | 2006-06-23 | 2007-06-21 | Use of colloidal gold as an adjuvant |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060057040A KR100836893B1 (ko) | 2006-06-23 | 2006-06-23 | 콜로이드 금의 아쥬반트로의 사용 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070122056A true KR20070122056A (ko) | 2007-12-28 |
KR100836893B1 KR100836893B1 (ko) | 2008-06-11 |
Family
ID=38833622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060057040A KR100836893B1 (ko) | 2006-06-23 | 2006-06-23 | 콜로이드 금의 아쥬반트로의 사용 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR100836893B1 (ko) |
WO (1) | WO2007148924A1 (ko) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100836745B1 (ko) * | 2007-01-31 | 2008-06-10 | (주)두비엘 | Hbv 백신 및 그의 제조 방법 |
US11324819B2 (en) * | 2016-04-06 | 2022-05-10 | University Of Washington | Therapeutic vaccine for Hepatitis b virus (HBV) using the HBV core antigen |
CN111163802A (zh) * | 2017-07-14 | 2020-05-15 | 公益财团法人东京都医学总合研究所 | 乙型肝炎疫苗 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPO347396A0 (en) * | 1996-11-04 | 1996-12-05 | Medical Innovations Limited | Synergistic gold-containing compositions |
US6407218B1 (en) * | 1997-11-10 | 2002-06-18 | Cytimmune Sciences, Inc. | Method and compositions for enhancing immune response and for the production of in vitro mabs |
-
2006
- 2006-06-23 KR KR1020060057040A patent/KR100836893B1/ko active IP Right Grant
-
2007
- 2007-06-21 WO PCT/KR2007/003002 patent/WO2007148924A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2007148924A1 (en) | 2007-12-27 |
KR100836893B1 (ko) | 2008-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100836745B1 (ko) | Hbv 백신 및 그의 제조 방법 | |
KR100517114B1 (ko) | 폴리감마글루탐산을 함유하는 면역보강제 조성물 | |
US20140205630A1 (en) | Compositions comprising a b subunit of shiga toxin and a means stimulating nkt cells | |
JP2011026328A (ja) | オリゴヌクレオチド組成物および免疫応答の調節のためのそれらの使用 | |
JP2009298806A (ja) | ポリヌクレオチドおよび必要に応じて抗原を含む、特にワクチン接種のための薬学的組成物 | |
CN1889977A (zh) | 含白介素18和皂苷佐剂系统的疫苗组合物 | |
TWI589298B (zh) | 陽離子之脂質疫苗組合物及其使用方法 | |
KR100850473B1 (ko) | 면역원성이 불량한 항원의 면역원성을 향상시키는 약제조성물 | |
US7279555B2 (en) | Advanced antigen presentation platform | |
KR101300905B1 (ko) | 백신으로서의 생물학적 활성제와 재조합 마이코박테리움의 조합물 | |
CN101115503A (zh) | 输送粘膜疫苗用的肽 | |
CA2719252C (en) | Anti-infective agents comprising muramyl dipeptide microparticles and uses thereof | |
TWI719351B (zh) | 於疫苗中作為佐劑的包含gm3神經節苷脂的合成變體之奈米粒子 | |
KR100836893B1 (ko) | 콜로이드 금의 아쥬반트로의 사용 | |
JP2017509642A (ja) | 細胞性の細胞傷害性免疫応答を誘導または延長する方法における使用のための医薬 | |
WO2000046365A1 (en) | Advanced antigen presentation platform | |
CA2418899A1 (fr) | Utilisation d'immunogenes pour traiter ou prevenir au sein des tumeurs malignes les dereglements immunitaires ou vasculaires induits par des facteurs extracellulaires | |
JP2005528899A (ja) | 抗原提示細胞の生成方法 | |
CA2588573C (en) | Immunotherapeutic formulations to generate autoantibodies capable to avoid the binding of interleukin-2 to its receptor their use in the treatment of cancer | |
US6844000B2 (en) | Use of Parapox B2L protein to treat cancer and modify immune responses | |
US8628785B2 (en) | Method for augmenting the immunogenicity of an antigen | |
EP4306641A1 (en) | Novel nucleic acid molecule | |
TW201718006A (zh) | 水生物種中增強之免疫反應 | |
Apostolopoulos et al. | Subunit protein-based vaccines | |
US20180055920A1 (en) | Vaccine, therapeutic composition and methods for treating or inhibiting cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130530 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20140602 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20150601 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20160601 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20170601 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20180525 Year of fee payment: 11 |